Ghidurile ESC - Media Med Publicis

multiple intr avenous adm inistration. Clin Phar macol Ther
1996;60:75–88.
119. Dormans T P, van Mey el JJ, Gerlag PG, Tan Y, Russel
FG, Smits P. D iuretic efficacy of high dose fu rosemide in
severe h eart f ailure: bo lus injection v ersus continuous
infusion. J Am Coll Cardiol 1996;28:376–382.
120. Maxwell AP, Ong HY, Nicholls DP. Influen ce o f
progressive ren al d ysfunction in chronic heart f ailure. Eur J
Heart Fail 2002;4:125–130.
121. Marik PE, Kussman BD, Lipman J, Kraus P.
Acetazolamide in the tr eatment of m etabolic alk alosis in
critically ill patients. Heart Lung 1991;20:455–459.
122. Sharpe N. Beta-blo ckers in heart failure. Future
directions. Eur Heart J 1996;17(Suppl. B):39–42.
123. Furberg CD. Overview of completed sudden death trials:
US experience. Cardiology 1987;74(Suppl. 2):24–31.
124. Yusuf S, Peto R, Lewis J, Collins R, Sl eight P. Beta
blockade during and af ter myocardial infarction: an overv iew
of the r andomized trials. Prog Cardiovasc Dis 1985;27:335–
371.
125. Herlitz J, Waagstein F, Lindqvist J, Swedberg K,
Hjalmarson A. Effect of meto prolol on the prognosis for
patients with s uspected acute m yocardial infarction and
indirect signs of congestive h eart failure (a subgroup analy sis
of the Goteborg Metoprolol Trial). Am J Cardiol 1997;80:40J–
44J.
126. Herlitz J, Elmfeldt D, Hj almarson A et al. Effect of
metoprolol on indirect signs of the size and s everity of acute
myocardial infarction. Am J Cardiol 1983;51:1282–1288.
127. Witch itz S, Cohen-Solal A, Dartois N, Weisslinger N,
Juste K, Darmon JY. Treatment of heart f ailure with
celiprolol, a cardioselective beta block er with beta-2 agonist
vasodilatory properties. The CELICARD Group. Am J Cardiol
2000;85:1467–1471.
128. Held PH, Corbeij HM, D unselman P, Hjalmarson A,
Murray D, Swedberg K. Hemodynamic effects of metoprolol
in acute my ocardial infarctio n. A randomized, placebocontrolled
multicenter study. Am J Cardiol 1985;56:47G–54G.
129. Katz AM. Potential deleterious effects of inotropic agents
in the th erapy of chron ic heart fa ilure. Circul ation
1986;73:III184–III190.
130. Packer M. The development of positive ino tropic agents
for chronic heart failure: how have we gone astray? J Am Coll
Cardiol 1993;22:119A–126A.
131. O’Connor CM, Gattis WA, Uretsk y BF et al. Continuous
intravenous dobutamine is associated with an increased risk of
death in patients with advanced heart failure: insights from the
Flolan International Randomized Survival Trial ( FIRST). Am
Heart J 1999;138:78–86.
132. Thackray S, Easthaugh J, Fr eemantle N, Cleland JG. The
effectiveness and relativ e ef fectiveness of intravenous
inotropic dru gs acting through the adr energic pathway in
patients with heart f ailure—a m eta-regression anal ysis.
2002;4:515–529.
133. Colu cci WS, Wright RF, Braunwald E. New positive
inotropic ag ents in th e treatment of congestive heart failure.
Mechanisms of act ion and recent clinical developments. 1. N
Engl J Med 1986;314:290–299.
134. Goldberg LI, McDonald RH Jr, Zimmerman AM.
Sodium diuresis produced b y dopamine in patients with
congestive heart failure. N Engl J Med 1963;269:1060–1064.
135. Maskin CS, Ocken S, Chadwick B, LeJemtel TH.
Comparative s ystemic and ren al eff ects of d opamine and
angiotensin-converting enzy me inhibition with enalaprilat in
patients with heart failure. Circulation 1985;72:846–852.
136. Metra M, Missale C, Span o PF, Cas LD. Dopaminergic
drugs in congestive heart failure: hemod ynamic and
neuroendocrine responses to ibopamine, d opamine, and
dihydroergotoxine. J Cardiovasc Pharmacol 1995;25:732–740.
137. Leier CV, Binkley PF. Par enteral inotropic support for
advanced cong estive h eart fa ilure. Prog Cardiovasc Dis
1998;41:207–224.
138. van de B orne P, Oren R, Somers VK. Dopamine
depresses minute ventilation in patien ts with heart f ailure.
Circulation 1998;98:126–131.
139. Bellomo R, Chapman M, Finfer S, Hickling K, My burgh
J. Low-dose dopamine in patients with early r enal
dysfunction: a placebo-controlled randomised trial. Australian
and New Z ealand Intens ive Care S ociety (ANZICS) Clinical
Trials Group. Lancet 2000;356:2139–2143.
140. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow
MR. Assessmen t of the beta-ad renergic recepto r pathway in
the inta ct fa iling hum an heart: progressive receptor downregulation
and s ubsensitivity to agonist response. Circu lation
1986;74:1290–1302.
141. Feldman MD, Copelas L, Gwa thmey JK et al. Deficient
production of cy clic AMP: pharmacologic evidence of an
important cause of contractile dysfunction in patients with
end-stage heart failure. Circulation 1987;75:331–339.
142. Colucci WS, Wright RF, Jaski BE, Fifer M A, Braunwald
E. Milrinone and dobutamine in severe heart failure: differing
hemodynamic effects and indiv idual p atient r esponsiveness.
Circulation 1986;73:III175–III183.
143. Galley HF. Renal-dose dop amine: will the message now
get through? Lancet 2000;356:2112–2113.
144. Lowes B D, Tsvetkov a T, Eichhorn EJ , Gilb ert EM,
Bristow MR. Milrinone versu s dobutamine in heart failure
subjects t reated chroni cally wi th c arvedilol. I nt J Cardio l
2001;81:141–149.
145. Metra M, Nodari S, D’ Aloia A et al. Beta-blo cker
therapy influences the hemody namic response to ino tropic
agents in patients with heart failure: a randomized comparison
of dobutamine and enoximone befor e and after chronic
treatment with metoprolol or carvedilol. J Am Coll Ca rdiol
2002;40:1248–1258.
146. Gilbert EM, Hershberger RE, Wiechmann RJ, Movsesian
MA, Bristow MR. Pharmacologic and hemodynamic effects of
combined betaagonist stim ulation and phosphodiester ase
inhibition in th e failing hum an heart . Chest 19 95;108:1524–
1532.
147. Levine TB, Levine AB, Elliott WG, Narins B, Stomel RJ.
Dobutamine as bridge to an giotensin-converting en zyme
inhibitor-nitrate therapy in endstage heart failure. Clin Cardiol
2001;24:231–236.
148. Caldicott LD, Hawley K, Heppell R, Woodmansey PA,
Channer KS. Intravenous enoximone or dobutamine for severe
heart failure after acute m yocardial infarction: a randomized
double-blind trial. Eur Heart J 1993;14:696–700.
149. Burger AJ, Horton DP, LeJemtel T et al. Effect of
nesiritide (B- type nat riuretic peptide) and d obutamine on
ventricular ar rhythmias in the treatm ent of patients with
acutely d ecompensated congestive h eart failure: th e
PRECEDENT study. Am Heart J 2002;144:1102–1108.
150. Schulz R, Rose J, Martin C, Brodde OE, Heusch G.
Development o f short-term my ocardial hib ernation. Its
limitation b y the sever ity o f ischem ia and inotropi c
stimulation. Circulation 1993;88:684–695.
151. Colu cci WS, Wright RF, Braunwald E. New positive
inotropic ag ents in th e treatment of congestive heart failure.
Mechanisms of act ion and recent clinical developments. 2. N
Engl J Med 1986;314:349–358.
152. Bohm M, Deutsch HJ, Hart mann D, Rosee KL, Stablein
A. Improvement of postreceptor even ts by metopro lol
treatment in pat ients with ch ronic hear t failur e. J Am Coll
Cardiol 1997;30:992–996.
153. Loh E, Elkayam U, Cody R, Bristow M, Jaski B, Colucci
WS. A randomi zed multicenter study comparing the eff icacy
and safety of intrav enous milrinone and intrav enous
38